These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 22989914)

  • 21. Waldenstrom macroglobulinemia cells devoid of BTK
    Paulus A; Akhtar S; Yousaf H; Manna A; Paulus SM; Bashir Y; Caulfield TR; Kuranz-Blake M; Chitta K; Wang X; Asmann Y; Hudec R; Springer W; Ailawadhi S; Chanan-Khan A
    Blood Cancer J; 2017 May; 7(5):e565. PubMed ID: 28548645
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bruton Kinase Inhibitors in Chronic Lymphocytic Leukemia.
    Gozzetti A; Candi V; Brambilla CZ; Papini G; Fabbri A; Bocchia M
    Anticancer Agents Med Chem; 2017; 17(8):1040-1045. PubMed ID: 27697038
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Role of Bruton's tyrosine kinase (BTK) in growth and metastasis of INA6 myeloma cells.
    Bam R; Venkateshaiah SU; Khan S; Ling W; Randal SS; Li X; Zhang Q; van Rhee F; Barlogie B; Epstein J; Yaccoby S
    Blood Cancer J; 2014 Aug; 4(8):e234. PubMed ID: 25083818
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibitor of Bruton's tyrosine kinases, PCI-32765, decreases pro-inflammatory mediators' production in high glucose-induced macrophages.
    Fan Z; Wang Y; Xu X; Wu Y
    Int Immunopharmacol; 2018 May; 58():145-153. PubMed ID: 29587203
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Preclinical investigation of ibrutinib, a Bruton's kinase tyrosine (Btk) inhibitor, in suppressing glioma tumorigenesis and stem cell phenotypes.
    Wei L; Su YK; Lin CM; Chao TY; Huang SP; Huynh TT; Jan HJ; Whang-Peng J; Chiou JF; Wu AT; Hsiao M
    Oncotarget; 2016 Oct; 7(43):69961-69975. PubMed ID: 27564106
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Analysis of the Effects of the Bruton's tyrosine kinase (Btk) Inhibitor Ibrutinib on Monocyte Fcγ Receptor (FcγR) Function.
    Ren L; Campbell A; Fang H; Gautam S; Elavazhagan S; Fatehchand K; Mehta P; Stiff A; Reader BF; Mo X; Byrd JC; Carson WE; Butchar JP; Tridandapani S
    J Biol Chem; 2016 Feb; 291(6):3043-52. PubMed ID: 26627823
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Bruton's tyrosine kinase inhibitor ibrutinib exerts immunomodulatory effects through regulation of tumor-infiltrating macrophages.
    Ping L; Ding N; Shi Y; Feng L; Li J; Liu Y; Lin Y; Shi C; Wang X; Pan Z; Song Y; Zhu J
    Oncotarget; 2017 Jun; 8(24):39218-39229. PubMed ID: 28424405
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ibrutinib targets microRNA-21 in multiple myeloma cells by inhibiting NF-κB and STAT3.
    Ma J; Gong W; Liu S; Li Q; Guo M; Wang J; Wang S; Chen N; Wang Y; Liu Q; Zhao H
    Tumour Biol; 2018 Jan; 40(1):1010428317731369. PubMed ID: 29320977
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeting Bruton's tyrosine kinase for the treatment of B cell associated malignancies and autoimmune diseases: Preclinical and clinical developments of small molecule inhibitors.
    Zhang Z; Zhang D; Liu Y; Yang D; Ran F; Wang ML; Zhao G
    Arch Pharm (Weinheim); 2018 Jul; 351(7):e1700369. PubMed ID: 29741794
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bruton's tyrosine kinase is a potential therapeutic target in prostate cancer.
    Kokabee L; Wang X; Sevinsky CJ; Wang WL; Cheu L; Chittur SV; Karimipoor M; Tenniswood M; Conklin DS
    Cancer Biol Ther; 2015; 16(11):1604-15. PubMed ID: 26383180
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ibrutinib and indolent B-cell lymphomas.
    Akinleye A; Furqan M; Adekunle O
    Clin Lymphoma Myeloma Leuk; 2014 Aug; 14(4):253-60. PubMed ID: 24445187
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeting Bruton's tyrosine kinase with ibrutinib in B-cell malignancies.
    Wang Y; Zhang LL; Champlin RE; Wang ML
    Clin Pharmacol Ther; 2015 May; 97(5):455-68. PubMed ID: 25669675
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bruton's tyrosine kinase (BTK) as a promising target in solid tumors.
    Molina-Cerrillo J; Alonso-Gordoa T; Gajate P; Grande E
    Cancer Treat Rev; 2017 Jul; 58():41-50. PubMed ID: 28641100
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bruton's tyrosine kinase inhibition increases BCL-2 dependence and enhances sensitivity to venetoclax in chronic lymphocytic leukemia.
    Deng J; Isik E; Fernandes SM; Brown JR; Letai A; Davids MS
    Leukemia; 2017 Oct; 31(10):2075-2084. PubMed ID: 28111464
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bruton's TK inhibitors: structural insights and evolution of clinical candidates.
    Xing L; Huang A
    Future Med Chem; 2014 Apr; 6(6):675-95. PubMed ID: 24895895
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bruton's Tyrosine Kinase Inhibitors Prevent Therapeutic Escape in Breast Cancer Cells.
    Wang X; Wong J; Sevinsky CJ; Kokabee L; Khan F; Sun Y; Conklin DS
    Mol Cancer Ther; 2016 Sep; 15(9):2198-208. PubMed ID: 27256378
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Use of BTK inhibitors with special focus on ibrutinib in Waldenström macroglobulinemia: An expert panel opinion statement.
    Ferrero S; Gentile M; Laurenti L; Mauro FR; Martelli M; Sportoletti P; Visco C; Zinzani PL; Tedeschi A; Varettoni M
    Hematol Oncol; 2022 Aug; 40(3):332-340. PubMed ID: 35212014
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bruton's tyrosine kinase inhibitor suppresses imiquimod-induced psoriasis-like inflammation in mice through regulation of IL-23/IL-17A in innate immune cells.
    Nadeem A; Ahmad SF; Al-Harbi NO; El-Sherbeeny AM; Alasmari AF; Alanazi WA; Alasmari F; Ibrahim KE; Al-Harbi MM; Bakheet SA; Attia SM
    Int Immunopharmacol; 2020 Mar; 80():106215. PubMed ID: 31982823
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Current Status of Bruton's Tyrosine Kinase Inhibitor Development and Use in B-Cell Malignancies.
    Aw A; Brown JR
    Drugs Aging; 2017 Jul; 34(7):509-527. PubMed ID: 28536906
    [TBL] [Abstract][Full Text] [Related]  

  • 40. MYD88-independent growth and survival effects of Sp1 transactivation in Waldenstrom macroglobulinemia.
    Fulciniti M; Amodio N; Bandi RL; Munshi M; Yang G; Xu L; Hunter Z; Tassone P; Anderson KC; Treon SP; Munshi NC
    Blood; 2014 Apr; 123(17):2673-81. PubMed ID: 24622324
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.